National Meeting on ZADAXIN(R) Use in Cancer Held in China; - New Liver Cancer One-Year Follow-Up Data Presented -
SAN MATEO, Calif., April 23 /PRNewswire Interactive News Release/ -- SciClone Pharmaceuticals (Nasdaq: SCLN - news) announced that approximately 800 cancer researchers and physicians, including China's top oncologists, gathered on Saturday, April 21st, at the Shanghai International Convention Center for the ``National ZADAXIN® Meeting on Cancer'' in the People's Republic of China. More than 40 papers and abstracts were submitted containing data resulting from cancer research and clinical experience using ZADAXIN, SciClone's immune system enhancer (ISE).
The meeting covered three broad topics, each the subject of a formal session: 1) treatments for cancer using ZADAXIN in combination with chemotherapy, surgery and other interventions; 2) use of ZADAXIN in the specific treatment of hepatocellular carcinoma (HCC); and 3) use of ZADAXIN in the prevention of chemotherapeutic adverse effects.
During the featured second session Dr. W.J. Zhang presented new one-year follow-up data from a study of HCC patients treated with ZADAXIN plus transarterial chemoembolization (TACE) led by Dr. Z.S. Li of Changhai Hospital and The Second Military Medical University. In this study, the combination treatment resulted in statistically significant improvement in survival rates at 6, 9 and 12 months following treatment of 91%, 88% and 78% respectively, compared to rates of 77%, 58% and 46% in a matched historical control group using TACE alone.
other than that....as long as the shorters have it, they'll keep it under 5...and there is NO institutional ownership anymore, so until that time that we get some serious results and serious sales somewhere else other than China.
chris |
